ArticleJournal of clinical pathology2007

Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.

S Di Palma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.